AstraZeneca (AZ) and its biologics R&D arm, MedImmune, have announced that the latest respiratory trial of Fasenra (benralizumab) in patients with moderate-to-very-severe chronic obstructive
While many of the hopes and disappointments for AstraZeneca's (AZ) business are around oncology, it still needs its cardiovascular and diabetes portfolio to perform.
New initiative helps countries focus on the policies most likely to benefit their populations in overcoming diabetes, explains Shaukat M Sadikot, President of the International Diabetes Federat
As we enter the home straight towards the end of 2016, Andrew McConaghie looks at the some of the most important events of the pharma and biotech year to date.
Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough